EUVIMEDEUVIMED entdecken
Crossref

EP300 promotes tumor stemness via epigenetic activation of CRISP3 leading to lobaplatin resistance in triple-negative breast cancer

Yan Wang, Yi Zhang, Xiaowei Qi

Human Cell · 2024

DOI: 10.1007/s13577-024-01091-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Cell, 2024. Verfasst von Yan Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, People's Republic of China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Resistance, Neoplasm, E1A-Associated p300 Protein, Epigenesis, Genetic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lobaplatin shows antitumor activity against a wide range of tumors, including triple-negative breast cancer (TNBC), and has been linked to cancer stem cell pool. Here, we investigated the molecular mechanisms behind lobaplatin resistance and stemness in vitro and in vivo. Two chemoresistance-related GEO data sets (GSE70690 and GSE103115) were included to screen out relevant genes. Cysteine-rich secretory protein 3 (CRISP3) was found to be overexpressed in lobaplatin-resistant TNBC and related to poor diagnosis. CRISP3 expression was significantly correlated with tumor stemness markers in lobaplatin-resistant cells. E1A-associated protein p300 (EP300) regulated CRISP3 expression by affecting the H3K27ac modification of the CRISP3 promoter. In addition, knocking down EP300 curbed the malignant biological behavior of lobaplatin-resistant cells, which was antagonized by CRISP3 overexpression. Collectively, our results highlight the EP300/CRISP3 axis as a key driver of lobaplatin resistance in TNBC and suggest that therapeutic targeting of this axis may be an effective strategy for enhancing platinum sensitivity in TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug Resistance, NeoplasmE1A-Associated p300 ProteinEpigenesis, GeneticNeoplastic Stem CellsSeminal Plasma ProteinsTriple Negative Breast NeoplasmsSalivary Proteins and PeptidesFemaleHumansCell Line, TumorCyclobutanesGene ExpressionGene Expression Regulation, NeoplasticOrganoplatinum Compounds

Stichwörter der Autor:innen

CRISP3EP300LobaplatinStemnessTriple-negative breast cancer

Substanzen

Antineoplastic AgentsCyclobutanesE1A-Associated p300 ProteinEP300 protein, humanlobaplatinOrganoplatinum CompoundsSeminal Plasma ProteinsCRISP3 protein, humanSalivary Proteins and Peptides

Autor:innen und Institutionen

  • Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, People's Republic of China.
  • Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, People's Republic of China. zhang_yy1008@163.com.
  • Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, People's Republic of China. qxw1611@163.com.

Zitieren

APA

Wang, Y., Zhang, Y., & Qi, X. (2024). EP300 promotes tumor stemness via epigenetic activation of CRISP3 leading to lobaplatin resistance in triple-negative breast cancer. Human Cell. https://doi.org/10.1007/s13577-024-01091-w

Vancouver

Wang Y, Zhang Y, Qi X. EP300 promotes tumor stemness via epigenetic activation of CRISP3 leading to lobaplatin resistance in triple-negative breast cancer. Human Cell. 2024. doi:10.1007/s13577-024-01091-w

BibTeX
@article{Wang2024,
  author = {Wang, Yan and Zhang, Yi and Qi, Xiaowei},
  title = {EP300 promotes tumor stemness via epigenetic activation of CRISP3 leading to lobaplatin resistance in triple-negative breast cancer},
  journal = {Human Cell},
  year = {2024},
  doi = {10.1007/s13577-024-01091-w}
}
Kostenlos starten →